Research programme: antibody-drug conjugate therapeutics - CelltrionAlternative Names: CT P26
Latest Information Update: 17 Mar 2016
At a glance
- Originator Celltrion
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Immunomodulators; Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 01 Mar 2014 Preclinical trials in Breast cancer in South Korea (unspecified route) before March 2014